Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis
- PMID: 40698047
- PMCID: PMC12279862
- DOI: 10.3389/fpsyt.2025.1565150
Threatening illness perception and associated factors in early-stage relapsing-remitting multiple sclerosis
Abstract
Background: Multiple sclerosis is one of the most common causes of neurological disability in young adults, with major consequences for their future lives. Patients with early-stage relapsing-remitting multiple sclerosis (RRMS) experience uncertainty and intense emotions as the diagnosis is disclosed. Illness perception at this point can influence levels of adjustment, coping strategies, treatment adherence, and well-being of the patient. However, there is limited information on patient illness perception surrounding the diagnosis.
Objective: The aim of this study was to assess illness perception and associated factors in early-stage RRMS patients.
Methods: A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS, a disease duration of ≤ 3 years, and an Expanded Disability Status Scale (EDSS) score of 0-5.5 were included. The Brief-Illness Perception Questionnaire (B-IPQ) was used to assess the patients' cognitive and emotional representations of their illness. Different patient-reported measures were used to gather information on pain, fatigue, mood/anxiety, quality of life, symptom severity, feelings of hopelessness, perception of stigma, cognition, hand dexterity, gait, and workplace difficulties. A multivariate logistic regression analysis was performed to assess the association between the patients' illness perception and demographic and clinical characteristics, as well as patient-reported outcomes.
Results: A total of 189 patients were included (mean age: 36.1 ± 9.4 years, 71.4% females, mean disease duration: 1.4 ± 0.8 years). The median EDSS score was 1.0 (interquartile range: 0.0-2.0). A total of 36.5% of the patients (n=69/189) had a moderate-to-high threatening illness perception, and 45.5% thought that their disease was caused by psychological factors. Higher EDSS scores, symptom severity, poorer psychological quality of life, perception of stigma, and greater hopelessness were predictors of moderate-to-high threatening illness perception.
Conclusions: Threatening illness perceptions are common among patients with early-stage RRMS. Identifying these beliefs and their associated factors, and establishing individualized interventions, may help patients deal with their condition.
Keywords: early-stage; illness perception; individualized interventions; patient-reported outcome measures; psychological factors; relapsing-remitting multiple sclerosis.
Copyright © 2025 Gómez-Ballesteros, Sainz de la Maza, Borges, Martín-Martínez, Sotoca, Alonso, Caminero, Borrega, Sánchez-Menoyo, Barrero-Hernández, Calles, Brieva, Blasco-Quílez, Dotor García-Soto, Rodríguez-Regal, Navarro-Cantó, Agüera, Garcés-Redondo, Carmona, Gabaldón-Torres, Forero, Hervás, Castillo-Triviño and Maurino.
Conflict of interest statement
SS received payment for lecturing or travel expenses from Merck-Serono, Biogen, Sanofi-Genzyme, Roche, and Novartis. RG-B and JM are employees of Roche Pharma Spain. JM-M has served on scientific advisory boards and/or has received speaking honoraria, research funding and support to attend scientific meetings from Biogen, Merck, Novartis, Roche and Teva. JS has received speaking honoraria, compensation for consulting services and support to attend scientific meetings from Almirall, Bayer, Biogen, Merck, Novartis, Sanofi, Roche and Teva. AA has received compensation for consulting services from Biogen, BMS, Sanofi, Roche, Janssen and Novartis, and speaking honoraria from Biogen, BMS, Sanofi, Roche, Janssen, Merck, Almirall, and Novartis. AC has received courses and honoraria for her participation as speaker/meeting moderator/symposia organizer from Alter, Almirall, Bayer, Bial, Biogen, Bristol-Myers-Squibb, Lilly, Merck-Serono, Mylan, Novartis, Roche, Sanofi-Genzyme, Teva, and UCB, and support to attend scientific meetings from Biogen, Bial, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. JS-M has received support to attend scientific meetings from Novartis, Merck, and Biogen, speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer, and Teva, and has participated in clinical trials from Biogen, Merck, and Roche. FB-H has received compensation for consulting services and speaking honoraria from Almirall, Biogen, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, and Teva. CC has received compensation for consulting services, speaking honoraria and support to attend scientific meetings and courses from Merck, Teva, Sanofi-Genzyme, Novartis, Biogen, Roche, and Bristol-Myers-Squibb. LBr has received compensation for consulting services, speaking honoraria and support to attend scientific meetings from Bayer, Celgene, Biogen, Genzyme, Merck, Novartis, Roche, Almirall and Teva. JDG-S has received compensation for consulting services and speaking honoraria from Biogen, Novartis, Merck, UCB, Sanofi-Genzyme, Roche, Almirall, and Teva. LN-C has received compensations from Sanofi-Genzyme, Merck, Biogen, and Roche. EA has received speaking honoraria from Roche, Novartis, Merck, Sanofi, and Biogen. MG-R has received speaking honoraria from Biogen, Sanofi, Almirall and Novartis. OC has participated in studies and has received speaking honoraria from Roche, Merck, Biogen, and Novartis. LG-T has received speaking honoraria from Biogen, Novartis, Merck, Bayer, Sanofi-Genzyme, Almirall, Roche and Teva. MH has participated in observational studies and has received compensation for consulting services and speaking honoraria from Roche, Merck, Sanofi, Biogen, Novartis and Bayer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Rituximab for relapsing-remitting multiple sclerosis.Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Cochrane Database Syst Rev. 2013. PMID: 24310855 Free PMC article.
-
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2. Cochrane Database Syst Rev. 2013. PMID: 23744561 Free PMC article.
-
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3. Cochrane Database Syst Rev. 2024. PMID: 38174776 Free PMC article.
-
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.Cochrane Database Syst Rev. 2015 Sep 18;2015(9):CD011381. doi: 10.1002/14651858.CD011381.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2024 Jan 4;1:CD011381. doi: 10.1002/14651858.CD011381.pub3. PMID: 26384035 Free PMC article. Updated.
-
Teriflunomide for multiple sclerosis.Cochrane Database Syst Rev. 2016 Mar 22;3(3):CD009882. doi: 10.1002/14651858.CD009882.pub3. Cochrane Database Syst Rev. 2016. PMID: 27003123 Free PMC article.
References
LinkOut - more resources
Full Text Sources